Laurel Wealth Advisors (North Carolina)’s BioMarin Pharmaceuticals BMRN Stock Holding History

Laurel Wealth Advisors (North Carolina)’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-160	Closed	-$13K	–	544
2022 Q2	$13K	Hold	160	–	–	﹤0.01%	368
2022 Q1	$12K	Hold	160	–	–	﹤0.01%	389
2021 Q4	$14K	Hold	160	–	–	﹤0.01%	377
2021 Q3	$12K	Hold	160	–	–	﹤0.01%	392
2021 Q2	$13K	Hold	160	–	–	﹤0.01%	428
2021 Q1	$12K	Buy	160 +40	+33%	+$3.27K	﹤0.01%	403
2020 Q4	$11K	Buy	+120	New	+$9.51K	﹤0.01%	401

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Laurel Wealth Advisors (North Carolina)'s BMRN Position: Q3 2022 in Review

Laurel Wealth Advisors (North Carolina) sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2022, closing a stake of 160 shares — an estimated $13K sold.

Laurel Wealth Advisors (North Carolina) first reported a position in BMRN in Q4 2020 and held it in 7 quarters. The position peaked at $14K in Q4 2021. 551 funds tracked by Wall St. Rank hold BMRN as of Q3 2022.

Laurel Wealth Advisors (North Carolina) reported no remaining BioMarin Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Laurel Wealth Advisors (North Carolina) sold 160 BioMarin Pharmaceuticals shares in Q3 2022, an estimated $13K.
Laurel Wealth Advisors (North Carolina) first reported a position in BioMarin Pharmaceuticals in Q4 2020 and held it in 7 quarters.
Laurel Wealth Advisors (North Carolina)'s BioMarin Pharmaceuticals position peaked at $14K in Q4 2021.
551 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2022.

Based on Laurel Wealth Advisors (North Carolina)'s 13F filing for Q3 2022, filed 15 Nov 2022.